Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice.
Dehydroevodiamine has been reported to have anticholinesterase activity and an anti-amnesic effect. This study examined the effects of dehydroevodiamine on scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia in mice, using a step-through passive avoidance test. Similarly to the cholinesterase inhibitor, physostigmine (0.03--0.3 mg/kg, i.p.), dehydroevodiamine (0.75--12.0 mg/kg, i.p.) administered 30 min before the training trial, immediately after the training trial, and 30 min before the retention test significantly improved scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia. In beta-amyloid peptide-(25--35)-induced amnesia, the rank order of anti-amnesic potency in these three administration schedules for dehydroevodiamine was different from that for physostigmine. Furthermore, dehydroevodiamine was more potent to improve beta-amyloid peptide-(25--35)-induced amnesia than scopolamine-induced amnesia when administered before the training trial. These results suggested that dehydroevodiamine may have an action other than that of an anticholinesterase and may be a novel and effective ligand for improvement of beta-amyloid type amnesia.
Department and Institute of Pharmacology, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Pei-Tou Dist. (112), Taipei (11221), Taiwan.
H H
HH
Wang
C J
CJ
Chou
J F
JF
Liao
C F
CF
Chen
D000470:Alkaloids / Q000008:administration & dosage*; D000544:Alzheimer Disease / Q000188:drug therapy; D000647:Amnesia / Q000139:chemically induced / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000009:adverse effects; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects* / Q000502:physiology; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D018727:Muscarinic Antagonists / Q000009:adverse effects; D010446:Peptide Fragments / Q000009:adverse effects; D010830:Physostigmine / Q000008:administration & dosage; D012601:Scopolamine / Q000009:adverse effects
D000470:Alkaloids; D016229:Amyloid beta-Peptides; D002800:Cholinesterase Inhibitors; D018727:Muscarinic Antagonists; D010446:Peptide Fragments; C074636:amyloid beta-protein (25-35); C028633:dehydroevodiamine; D010830:Physostigmine; D012601:Scopolamine